Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 9/20 | 0.59 |
| ▸ | ADRA2C | P18825 | 9/20 | 0.59 |
| ▸ | ADRA2B | P18089 | 5/20 | 0.55 |
| ▸ | KDM1A | O60341 | 4/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.53 |
| ▸ | DRD1 | P21728 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.53 |
| ▸ | HTR1D | P28221 | 1/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.53 |
| ▸ | HTR7 | P34969 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | HRH1 | P35367 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7126445 | 0.86 | KDM1A (0.72) | ADRA2AADRA2CADRA2BKDM1AGLA | |
| SCHEMBL7116931 | 0.85 | KDM1A (0.71) | ADRA2AADRA2CADRA2BKDM1AGLA | |
| SCHEMBL7124417 | 0.82 | ADRA2A (0.52) | ADRA2AADRA2CADRA2BKDM1AGLA | |
| SCHEMBL7119489 | 0.73 | ACHE (0.58) | ADRA2AADRA2CADRA2BKDM1AGLA | |
| SCHEMBL1664525 | 0.71 | KDM1A (1.00) | ADRA2AADRA2CADRA2BKDM1AGLA | |
| SCHEMBL12128598 | 0.71 | FLT3 (0.48) | ADRA2AADRA2CADRA2BKDM1AGLA | |
| SCHEMBL7127013 | 0.70 | KDM1A (0.67) | ADRA2AADRA2CADRA2BKDM1AGLA | |
| SCHEMBL7839012 | 0.69 | ADRA2A (0.57) | ADRA2AADRA2CADRA2BKDM1AGLA | |
| SCHEMBL12128637 | 0.69 | FLT3 (0.48) | ADRA2AADRA2CADRA2BKDM1AGLA | |
| SCHEMBL4078840 | 0.68 | EGFR (0.60) | ADRA2AADRA2CADRA2BKDM1AGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1468224-A | Quinoline derivatives as alpha-2 antagonists | — | 2004-01-14 | — | — | CN | claimed |
| US-20030225078-A1 | Derivatives of quinoline as alpha-2 antagonists | ORION CORPORATION | 2003-12-04 | — | — | US | claimed |
| EP-1263733-A2 | DERIVATIVES OF QUINOLINE AS ALPHA-2 ANTAGONISTS | ORION CORPORATION FARMOS (FI) | 2002-12-11 | — | — | EP | claimed |
| US-20010046991-A1 | Derivatives of quinoline as alpha-2 antagonists | OY JUVANTIA PHARMA LTD. (FI) | 2001-11-29 | — | — | US | claimed |
| WO-2001064645-A2 | DERIVATIVES OF QUINOLINE AS ALPHA-2 ANTAGONISTS | ORION CORPORATION (FI) | 2001-09-07 | — | — | WO | claimed |
| CN-1468224-A | Quinoline derivatives as alpha-2 antagonists | — | 2004-01-14 | — | — | CN | disclosed |
| US-20030225078-A1 | Derivatives of quinoline as alpha-2 antagonists | ORION CORPORATION | 2003-12-04 | — | — | US | disclosed |
| US-6593324-B2 | P-aminoanilino- derivatives | ORION CORPORATION (FI) | 2003-07-15 | — | — | US | disclosed |
| EP-1263733-A2 | DERIVATIVES OF QUINOLINE AS ALPHA-2 ANTAGONISTS | ORION CORPORATION FARMOS (FI) | 2002-12-11 | — | — | EP | disclosed |
| US-20010046991-A1 | Derivatives of quinoline as alpha-2 antagonists | OY JUVANTIA PHARMA LTD. (FI) | 2001-11-29 | — | — | US | disclosed |
| WO-2001064645-A2 | DERIVATIVES OF QUINOLINE AS ALPHA-2 ANTAGONISTS | ORION CORPORATION (FI) | 2001-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225078-A1 | Derivatives of quinoline as alpha-2 antagonists | ADRB2, ADRA2A, ADRB1 | ADRA2A 2/4885ADRA2C 6/4885ADRA2B 5/4885 |
| US-20010046991-A1 | Derivatives of quinoline as alpha-2 antagonists | ADRB2, ADRA2A, ADRB1 | ADRA2A 2/4885ADRA2C 6/4885ADRA2B 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.